After years of wondering if any drug could inherit Keytruda’s cancer immunotherapy crown, investors are increasingly convinced Akeso and Summit Therapeutics’s ivonescimab could be it.
Aiming For Keytruda’s Crown, Summit Raises Extra Funds To Fuel Ivonescimab Ambitions
The US company believes it can not only beat Keytruda at its own game, but also achieve success where Merck & Co's blockbuster and other immunotherapies have failed.
More from Clinical Trials
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.